Frankfurt - Delayed Quote • EUR
Eli Lilly and Company (LLY.F)
As of 5:16 PM GMT+2. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 14 | 14 |
| Avg. Estimate | 2.34 | 2.56 | 11.57 | 16.79 |
| Low Estimate | 2.07 | 2.29 | 11.08 | 13.69 |
| High Estimate | 2.6 | 2.83 | 11.91 | 19.21 |
| Year Ago EPS | 1.49 | 2 | 5.9 | 11.57 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 8 | 13 | 13 |
| Avg. Estimate | 8.28B | 9.16B | 38.54B | 47.99B |
| Low Estimate | 7.95B | 8.93B | 37.74B | 44.43B |
| High Estimate | 8.61B | 9.38B | 39.49B | 52.19B |
| Year Ago Sales | -- | -- | 31.88B | 38.54B |
| Sales Growth (year/est) | -- | -- | 20.90% | 24.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.57 | 1.86 | 0.01 | 2.13 |
| EPS Actual | 1.49 | 2 | 0.09 | 2.33 |
| Difference | -0.08 | 0.14 | 0.08 | 0.2 |
| Surprise % | -5.10% | 7.50% | 800.00% | 9.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 2.34 | 2.56 | 11.57 | 16.79 |
| 7 Days Ago | 2.35 | 2.63 | 11.67 | 16.96 |
| 30 Days Ago | 2.38 | 2.56 | 11.48 | 16.81 |
| 60 Days Ago | 2.37 | 2.54 | 11.48 | 16.81 |
| 90 Days Ago | 2.25 | 2.47 | 11.49 | 16.6 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | -- | 1 | -- |
| Up Last 30 Days | 3 | 2 | 1 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 2 | 2 | 3 |
Growth Estimates
| CURRENCY IN USD | LLY.F | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 57.00% | -- | -- | 1.50% |
| Next Qtr. | 28.00% | -- | -- | 11.40% |
| Current Year | 96.10% | -- | -- | 5.20% |
| Next Year | 45.10% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 48.20% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -4.62% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/15/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 4/11/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
| Upgrade | Erste Group: Hold to Buy | 4/3/2024 |
| Maintains | Citigroup: Buy to Buy | 4/2/2024 |
Related Tickers
BRM.F Bristol-Myers Squibb Company
42.11
-7.45%
JNJ.DE Johnson & Johnson
137.00
-0.57%
PFE.DE Pfizer Inc.
23.85
-2.43%
NOVN.SW Novartis AG
90.00
+0.99%
AZN.L AstraZeneca PLC
12,026.00
+5.94%
BAYN.DE Bayer Aktiengesellschaft
26.90
-0.28%
AZN AstraZeneca PLC
75.46
+5.98%
MRK Merck & Co., Inc.
129.91
+2.29%
ABBV AbbVie Inc.
166.78
-0.61%
PFE Pfizer Inc.
25.51
-2.91%